The artificial intelligence (AI) revolution continues to tout developing drugs faster and at lower cost, but are we there yet? On October 2nd, the FDA cleared an investigational new drug (IND) ...

SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a demonstration of ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

Announcing an artificial intelligence (AI) drug discovery partnership with Nvidia earlier this month, Recursion co-founder and CEO Chris Gibson, PhD, spoke as much about dollars as he did about drugs ...

There's a lot to like about the company using automation and artificial intelligence to improve the new drug-discovery process. Investors looking for stocks that can make dramatic gains often turn ...